Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda Buys U.S. Cancer Drug Firm

by Jean-François Tremblay
May 25, 2009 | A version of this story appeared in Volume 87, Issue 21

Takeda Pharmaceutical will pay roughly $75 million to acquire IDM Pharma, a cancer drug discovery and development firm located in Irvine, Calif. IDM's main asset is mifamurtide, a drug used to treat malignant bone cancer in children and young adults after the tumor has been removed. Although the European Commission approved mifamurtide in March, IDM has so far failed to secure regulatory approval in the U.S. Takeda says its U.S. oncology subsidiary Millennium will run IDM.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.